1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance, dependence and

Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance, dependence and

  1. Hanjo
    Abstract

    Ultra-low-dose opioid antagonists, when
    combined with opiates, increase the analgesic efficacy
    and duration of analgesia of the opiate. This
    enhanced and prolonged analgesia was recently
    demonstrated in a 350-patient Phase II clinical trial
    of OxytrexTM, a novel drug candidate that combines
    oxycodone with an ultra-low dose of the opioid
    antagonist naltrexone. Extensive preclinical data also
    show that the addition of ultra-low-dose opioid
    antagonists prevents analgesic tolerance to opiates as
    well as opioid dependence, measured by withdrawal
    signs. These drug combinations can also reverse
    established tolerance in rodents, unlike many other
    approaches shown to alleviate tolerance. The
    mechanism of action of ultra-low-dose opioid
    antagonists has been shown to be the prevention of
    excitatory signaling of opioid receptors, a
    phenomenon that opposes the normal inhibitory